| Outcome Measures: |
Primary: The change in liver fat content, The primary outcome measure will be the difference of the change in liver fat content from 0 (baseline) to 24 weeks between groups, Baseline to 24 Weeks | Secondary: The change in pancreatic fat, The difference of the change in pancreatic fat content from 0 (baseline) to 24 weeks between groups. \[Pancreatic fat content as quantified by MRI PDFF\], Baseline to 24 Weeks|The change in controlled attenuation parameter, The difference of the change in controlled attenuation parameter (CAP) from 0 (baseline) to 24 weeks between groups. \[CAP will be assessed by transient elastography\]., Baseline to 24 Weeks|The change in liver stiffness measurement (LSM), The difference of the change in liver stiffness measurement (LSM) from 0 (baseline) to 24 weeks between groups. \[LSM will be measured by transient elastography\]., Baseline to 24 Weeks|Change between the groups in aspartate aminotransferase (AST) levels, Change between the groups in aspartate aminotransferase (AST) levels, Baseline to 24 Weeks|Change between groups in alanine aminotransferase (ALT) levels, Change between groups in alanine aminotransferase (ALT) levels, Baseline to 24 Weeks|Change between groups in gamma-glutamyl transpeptidase (GGT) levels., Change between groups in gamma-glutamyl transpeptidase (GGT) levels., Baseline to 24 Weeks|Change between the groups in serum creatinine concentrations., Change between the groups in serum creatinine concentrations., Baseline to 24 Weeks|Change between the groups in total cholesterol levels., Change between the groups in total cholesterol levels., Baseline to 24 Weeks|Change between groups in triglycerides levels., Change between groups in triglycerides levels., Baseline to 24 Weeks|Change between groups in LDL levels, Change between groups in LDL levels, Baseline to 24 Weeks|Change between groups in HDL levels, Change between groups in HDL levels, Baseline to 24 Weeks
|
